DK1845978T3 - Substituerede pyrazolopyridiner, sammensætninger, som indeholder disse, fremgangsmåde til fremstilling heraf, og anvendelse heraf - Google Patents

Substituerede pyrazolopyridiner, sammensætninger, som indeholder disse, fremgangsmåde til fremstilling heraf, og anvendelse heraf

Info

Publication number
DK1845978T3
DK1845978T3 DK06709121.5T DK06709121T DK1845978T3 DK 1845978 T3 DK1845978 T3 DK 1845978T3 DK 06709121 T DK06709121 T DK 06709121T DK 1845978 T3 DK1845978 T3 DK 1845978T3
Authority
DK
Denmark
Prior art keywords
processes
preparation
compositions containing
substituted pyrazolopyridines
pyrazolopyridines
Prior art date
Application number
DK06709121.5T
Other languages
English (en)
Inventor
Baptiste Ronan
Michel Tabart
Frank Halley
Eric Bacque
Catherine Souaille
Antonio Ugolini
Fabrice Viviani
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36593766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1845978(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0500555A external-priority patent/FR2880891B1/fr
Priority claimed from FR0507505A external-priority patent/FR2888579A1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of DK1845978T3 publication Critical patent/DK1845978T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK06709121.5T 2005-01-19 2006-01-18 Substituerede pyrazolopyridiner, sammensætninger, som indeholder disse, fremgangsmåde til fremstilling heraf, og anvendelse heraf DK1845978T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0500555A FR2880891B1 (fr) 2005-01-19 2005-01-19 Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation
FR0507505A FR2888579A1 (fr) 2005-07-13 2005-07-13 Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation
PCT/FR2006/000114 WO2006077319A1 (fr) 2005-01-19 2006-01-18 Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation

Publications (1)

Publication Number Publication Date
DK1845978T3 true DK1845978T3 (da) 2010-12-13

Family

ID=36593766

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06709121.5T DK1845978T3 (da) 2005-01-19 2006-01-18 Substituerede pyrazolopyridiner, sammensætninger, som indeholder disse, fremgangsmåde til fremstilling heraf, og anvendelse heraf

Country Status (24)

Country Link
US (2) US8008322B2 (da)
EP (1) EP1845978B1 (da)
JP (1) JP2008527025A (da)
KR (1) KR20070098923A (da)
AR (1) AR052357A1 (da)
AT (1) ATE477799T1 (da)
AU (1) AU2006207442A1 (da)
BR (1) BRPI0606504A2 (da)
CA (1) CA2595041A1 (da)
CY (1) CY1110926T1 (da)
DE (1) DE602006016233D1 (da)
DK (1) DK1845978T3 (da)
HR (1) HRP20100624T8 (da)
IL (1) IL184524A0 (da)
MX (1) MX2007008790A (da)
PA (1) PA8660301A1 (da)
PE (1) PE20061119A1 (da)
PL (1) PL1845978T3 (da)
PT (1) PT1845978E (da)
RU (1) RU2375360C2 (da)
SI (1) SI1845978T1 (da)
TW (1) TW200639173A (da)
UY (1) UY29341A1 (da)
WO (1) WO2006077319A1 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2871158A1 (fr) 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
TW200815438A (en) * 2006-06-13 2008-04-01 Bayer Schering Pharma Ag Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP1870410A1 (en) 2006-06-13 2007-12-26 Bayer Schering Pharma Aktiengesellschaft Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP2125808A2 (en) * 2006-12-15 2009-12-02 Bayer Schering Pharma Aktiengesellschaft 3-h-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP1932845A1 (en) * 2006-12-15 2008-06-18 Bayer Schering Pharma Aktiengesellschaft 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP2042500A1 (en) * 2007-09-21 2009-04-01 Bayer Schering Pharma Aktiengesellschaft N-[4-(1-H-pyrazolo[3,4-c]pyridin-4-yl)phenyl]-N'-[(hetero)aryl]-urea compounds, pharmaceutical compositions comprising them, their preparation and their use as Tie2-kinase inhibitors
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
CA2704266A1 (en) * 2007-11-02 2009-06-11 Vertex Pharmaceuticals Incorporated [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta
EP2070929A1 (en) 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
US8841304B2 (en) 2008-01-08 2014-09-23 Array Biopharma, Inc. Pyrrolopyridines as kinase inhibitors
CN101965347B (zh) 2008-01-09 2013-01-02 阵列生物制药公司 作为激酶抑制剂的吡唑并吡啶
US8637542B2 (en) * 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US8993580B2 (en) * 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
JP5788316B2 (ja) 2008-07-08 2015-09-30 インテリカイン, エルエルシー キナーゼインヒビターおよび使用方法
US8476431B2 (en) * 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
MX2011009807A (es) * 2009-03-19 2011-09-29 Medical Res Council Technology Compuestos.
EP2464647B1 (en) 2009-08-11 2016-09-21 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
US8222416B2 (en) * 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
GB201008134D0 (en) * 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
CN103209960A (zh) 2010-07-26 2013-07-17 百时美施贵宝公司 用作cyp17抑制剂的磺酰胺化合物
GB201015949D0 (en) * 2010-09-22 2010-11-03 Medical Res Council Technology Compounds
US9266880B2 (en) 2010-11-12 2016-02-23 Bristol-Myers Squibb Company Substituted azaindazole compounds
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
US20140161720A1 (en) * 2011-05-26 2014-06-12 The General Hospital Corporation Treatment of angiogenic- or vascular-associated diseases
JP6133291B2 (ja) * 2011-08-12 2017-05-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ピラゾロ[3,4−c]ピリジン化合物と使用方法
WO2013125543A1 (ja) * 2012-02-20 2013-08-29 武田薬品工業株式会社 複素環化合物
WO2014052563A2 (en) * 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
BR112015015477B1 (pt) 2012-12-28 2022-07-12 Crystalgenomics, Inc Derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk
TWI629275B (zh) * 2013-03-13 2018-07-11 賽諾菲公司 N-(4-(氮雜吲唑-6-基)-苯基)-磺醯胺及其作為醫藥之用途
CN103524421B (zh) * 2013-09-29 2015-04-01 镇江蓝德特药业科技有限公司 新型萘脲类衍生物及其医疗应用
CA3092625A1 (en) 2018-04-05 2019-10-10 Merck Patent Gmbh Heteroaryl compounds as type ii irak inhibitors and uses thereof
UY38349A (es) 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
JP2025501767A (ja) * 2021-12-22 2025-01-23 アナシス・ファルマ・プロプライエタリー・リミテッド アリールスルホンアミド化合物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1182896B (de) * 1963-04-02 1964-12-03 Merck Ag E Fungizide Mittel
PL354241A1 (en) 1999-09-17 2003-12-29 Abbott Gmbh & Co.Kgabbott Gmbh & Co.Kg Kinase inhibitors as therapeutic agents
US20030232860A1 (en) * 2000-07-18 2003-12-18 Hironori Harada Medicine comprising dicyanopyridine derivative
ES2349762T3 (es) * 2000-08-10 2011-01-11 Pfizer Italia S.R.L. Biciclo-pirazoles activos como inhibidores de quinasas, procedimientos para su preparación y composiciones farmacéuticas que los comprenden.
JP4272338B2 (ja) * 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
FR2827603B1 (fr) 2001-07-18 2003-10-17 Oreal Composes derives de diaminopyrazole substitues par un radical heteroaromatique et leur utilisation en teinture d'oxydation des fibres keratiniques
GB0128287D0 (en) * 2001-11-26 2002-01-16 Smithkline Beecham Plc Novel method and compounds
JP2006514918A (ja) * 2002-07-23 2006-05-18 スミスクライン ビーチャム コーポレーション キナーゼインヒビターとしてのピラゾロピリミジン
EP1545515A1 (en) * 2002-08-12 2005-06-29 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
KR101312736B1 (ko) * 2003-02-27 2013-09-27 팔라우 파르마 에스에이 피라졸로피리딘 유도체
EP1620095A4 (en) 2003-04-24 2009-04-01 Merck & Co Inc HEMMER OF ACT ACTIVITY
JP4810427B2 (ja) * 2003-05-22 2011-11-09 アボット・ラボラトリーズ インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤
JP4836788B2 (ja) 2003-07-23 2011-12-14 エグゼリクシス, インコーポレイテッド 未分化リンパ腫キナーゼ変調因子及びその使用法
JP2005325099A (ja) * 2004-04-12 2005-11-24 Sankyo Co Ltd チエノピリジン誘導体
EP1753428A4 (en) * 2004-05-14 2010-09-15 Abbott Lab INHIBITORS OF KINASES AS THERAPEUTIC AGENTS
FR2871158A1 (fr) 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
US7812166B2 (en) * 2004-10-29 2010-10-12 Abbott Laboratories Kinase inhibitors
US7563781B2 (en) 2005-01-14 2009-07-21 Janssen Pharmaceutica Nv Triazolopyrimidine derivatives
EP1683796A1 (en) * 2005-01-24 2006-07-26 Schering Aktiengesellschaft Pyrazolopyridines, their preparation and their medical use
CA2601628C (en) 2005-03-10 2014-05-13 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2007056582A1 (en) 2005-11-09 2007-05-18 Memory Pharmaceuticals Corporation 1 h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
TW200815437A (en) * 2006-06-13 2008-04-01 Bayer Schering Pharma Ag Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP1870410A1 (en) * 2006-06-13 2007-12-26 Bayer Schering Pharma Aktiengesellschaft Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
TW200815438A (en) * 2006-06-13 2008-04-01 Bayer Schering Pharma Ag Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same

Also Published As

Publication number Publication date
US20080039491A1 (en) 2008-02-14
EP1845978B1 (fr) 2010-08-18
EP1845978A1 (fr) 2007-10-24
UY29341A1 (es) 2006-08-31
PT1845978E (pt) 2010-11-29
WO2006077319A1 (fr) 2006-07-27
KR20070098923A (ko) 2007-10-05
US20110190337A1 (en) 2011-08-04
PA8660301A1 (es) 2006-09-08
RU2007131274A (ru) 2009-02-27
DE602006016233D1 (de) 2010-09-30
CY1110926T1 (el) 2015-06-10
US8008322B2 (en) 2011-08-30
PL1845978T3 (pl) 2011-02-28
HRP20100624T1 (hr) 2010-12-31
CA2595041A1 (fr) 2006-07-27
TW200639173A (en) 2006-11-16
SI1845978T1 (sl) 2010-12-31
IL184524A0 (en) 2007-10-31
PE20061119A1 (es) 2006-11-27
BRPI0606504A2 (pt) 2009-06-30
JP2008527025A (ja) 2008-07-24
AU2006207442A1 (en) 2006-07-27
HRP20100624T8 (hr) 2011-01-31
RU2375360C2 (ru) 2009-12-10
ATE477799T1 (de) 2010-09-15
MX2007008790A (es) 2007-09-11
AR052357A1 (es) 2007-03-14

Similar Documents

Publication Publication Date Title
DK1845978T3 (da) Substituerede pyrazolopyridiner, sammensætninger, som indeholder disse, fremgangsmåde til fremstilling heraf, og anvendelse heraf
DK2074122T3 (da) Pyrido (2, 3-D) pyrimidinon-forbindelser og anvendelse deraf som P13 inhibitorer
DK2076260T3 (da) N-methylaminomethyl-isoindol-forbindelser og sammensætninger, der indeholder disse, samt fremgangsmåder til deres anvendelse
DK1960352T3 (da) 2-adamantylurinstof-derivater som selektive 11beta-hsd1 inhibitorer
DK1948149T4 (da) Formulering, som omfatter metformin og vildagliptin
DK1888580T3 (da) Pyrido[2,3-D]pyrimidiner, der er egnede som HCV-hæmmere, og fremgangsmåde til fremstillingen af disse
DK2069352T3 (da) Bestemte kemiske enheder, sammensætninger og fremgangsmåder
DK1868999T3 (da) Pyridin-3-carboxamidderivater som omvendte CB1-agonister
DK2010501T3 (da) Imidazolbaserede forbindelser, sammensætninger omfattende disse og fremgangsmåder for deres anvendelse
DK1849470T4 (en) Cancerlægemiddel, som indeholder alpha, alpha, alpha-trifluorthymidin og thymidin-phosphorylase-inhibitor
DK1896364T3 (da) Pulverformet kalksammensætning, fremgangsmåde til fremstilling deraf og anvendelse deraf
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
DK1765327T3 (da) Forbindelser, sammensætninger og fremgangsmåder
DK2044076T3 (da) Fremgangsmåde til fremstilling af asenapin og intermediatprodukter, som anvendes i fremgangsmåden
DK1928879T3 (da) Kondenserede heterocykliske forbindelser og anvendelse heraf som kinase-modulatorer
DK1713806T3 (da) Forbindelser og sammensætninger som proteinkinaseinhibitorer
NO20083147L (no) Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse
DK2049478T3 (da) Substituerede N-phenylmethyl-5-oxoprolin-2-amider som P2X7-receptorantagonister og fremgangsmåder til anvendelse deraf
NO20055686L (no) Sammensetning, fremgangsmate til fremstilling derav, og anvendelse derav.
DK2036892T3 (da) 1,2,4,5-tetrahydro-3H-benzazepinforbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
DK1670458T3 (da) 1-Amino-2-oxy-substituerede tetrahydronaphthalenderivater, fremgangsmåder til fremstilling deraf og deres anvendelse som antiphlogistika
NO20082256L (no) Pyrazolderivater, preparater som inneholder slike forbindelser, og fremgangsmåter for anvendelse
DK1877409T3 (da) Substituerede pyrrolopyridiner, sammensætninger, der indeholder samme, fremgangsmåde til fremstilling deraf samt anvendelse deraf
DK2107055T3 (da) Dosmetinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
NO20091520L (no) Skummende blandinger og fremgangsmåter for fremstilling av disse